AIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic Cancer
View original at globenewswire.comAIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic Cancer Positive Data from Named Patient Program and Positive Interim Data from Ongoing Phase 2 Clinical Trial Segment featuring Professor Doctor Casper H.J…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Ampligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that has shown broad-spectrum activity in clinical trials
60% confidenceNamed Patient Program showed Overall Survival of 19.7 months vs 12.5 months for historical controls, an improvement of 7.2 months
60% confidenceAmong NPP patients with CA 19-9 less than 1000, PFS was 13.1 months vs 8.6 months historical controls, an improvement of 4.5 months
60% confidenceAmong NPP patients with Neutrophil/Lymphocyte ratio less than 4.5, PFS was 17.7 months vs 8.6 months historical controls, an improvement of 9.1 months
60% confidenceAmong NPP patients with Neutrophil/Lymphocyte ratio less than 4.5, OS was 34.8 months vs 12.5 months historical controls, an improvement of 22.3 months
60% confidenceClinical experience in both the NPP and DURIPANC suggest consistent improvement in Quality of Life
60% confidenceDURIPANC enrollment completion, Mid-Year 2026 report, and key milestones are expected in June 2026
60% confidenceDURIPANC is a follow-up to the Named Patient Program and evaluates Ampligen in combination with AstraZeneca's Imfinzi in metastatic pancreatic cancer post-FOLFIRINOX
60% confidencePancreatic cancer is a lethal malignancy with a significant unmet medical need
60% confidenceAmong NPP patients with CA 19-9 less than 1000, OS was 24.1 months vs 12.5 months historical controls, an improvement of 11.6 months
60% confidenceNamed Patient Program showed Progression-Free Survival of 12.6 months vs 8.6 months for historical controls, an improvement of 4 months
60% confidenceAmpligen has potential to provide a positive immunotherapeutic approach for late-stage pancreatic cancer based on its mechanism of action and existing clinical data
60% confidence
Cited in these Via News reports
- FDA's H2 2026 Drug Decision Cluster Triggers Global Biotech Repricing in ADCs and Cell Therapies →
- Global ADC Combination Race Peaks in 2026–2027, Compressing Binary Risk Across Three Continents →
- Six FDA Oncology Decisions Due in 2026 — ADCs, Cell Therapies, and Checkpoint Inhibitors Face Global Catalyst Calendar →
- Vepdegestrant's 5-Month PFS Anchors Cross-Border Oncology Deals as 2026 PDUFA Cluster Reshapes Global Drug Valuations →